Circular Genomics (Scale Up Cohort 8) is a leader in precision psychiatric and neurologic medicine, dedicated to advancing personalized care through biotechnology. Through circular RNA biomarkers, Circular Genomics is creating new diagnostic and treatment solutions for psychiatric and neurological disorders. Their work empowers individuals to gain deeper insights into their mental and brain health, enabling more accurate and effective treatments.

Circular Genomics has developed MindLight™, the world’s first circular RNA-based test to predict antidepressant response for patients with Major Depressive Disorder (MDD). MindLight™ identifies if a patient is likely to respond to selective serotonin reuptake inhibitors (SSRIs), streamlining the treatment process and reducing the traditional trial-and-error approach. Through MindLight™ and ongoing innovations, Circular Genomics aims to improve the standard of care in mental health by offering data-driven solutions that enhance diagnosis and treatment selection for psychiatric and neurological conditions.

Circular Genomics has secured $8.3 million in Series A funding, led by Mountain Group Partners, to expand its commercial operations and advance toward the launch of the world’s first clinical assay based on circular RNA. This milestone will enable the company to meet a vital healthcare need and enhance patient care efficiency.

What problem is Circular Genomics solving? Circular Genomics addresses the challenge of diagnosing and treating psychiatric and neurological disorders. Their work with circular RNA biomarkers enables more precise diagnoses and helps clinicians predict patient responses to specific treatments, aiming to improve patient outcomes and reduce treatment delays.

What’s innovative about Circular Genomics? Circular Genomics is the global pioneer in using circular RNA as a biomarker for psychiatric and neurological conditions. They’ve developed MindLight™, the first-ever test that uses brain-derived circular RNA to predict an MDD patient’s response to SSRI antidepressants.

Who can use Circular Genomics? Clinicians, psychiatrists, neurologists, and healthcare providers working in mental health and neurology can use Circular Genomics’ solutions to enhance diagnosis and treatment for patients with psychiatric and neurological disorders.